Pharmacoeconomics of spastic cerebral palsy
Cerebral palsy (CP) is one of the most widespread and socially significant neurological diseases that affect both various aspects of physical and psychoverbal development of children since birth and stages of their personal development and adaptation in society. Over the last years there has been an...
Saved in:
Main Authors: | R. I. Yagudina, A. U. Kulikov, N. I. Korolyova, D. T. Ugrekhelidze |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2018-02-01
|
Series: | Регуляторные исследования и экспертиза лекарственных средств |
Subjects: | |
Online Access: | https://www.vedomostincesmp.ru/jour/article/view/55 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomics of HIV-infection
by: R. I. Yagudina, et al.
Published: (2018-02-01) -
Pharmacoeconomics of chronic kidney disease
by: R. I. Yagudina, et al.
Published: (2018-02-01) -
Фармакоэкономическое обоснование преимуществ индивидуального дозирования аминогликозидов: анализ затрат и эффективности
Published: (2020-04-01) -
PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION
by: A. Yu. Kulikov, et al.
Published: (2015-03-01) -
COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
by: R. I. Yagudina, et al.
Published: (2015-03-01)